Creative Medical Technology (CELZ) said Thursday the US Food and Drug Administration has allowed an increased dosing plan in its ongoing phase 1/2 trial of its cell therapy targeting chronic lower back pain caused by degenerative disc disease.
The decision follows interim blinded results showing significant pain reduction and mobility improvements with the use of CELZ-201-DDT among trial participants, the company said.
The FDA authorization allows the trial to move forward with dose escalation, which has already been approved by the study's safety and ethics boards.
Creative Medical said no serious side effects or dose-limiting toxicities have been reported halfway through the study.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。